8-K filing — Valion Bio, Inc. (VBIO)
Filed: 2026-10-06 AccNo: 0001437749-26-032107 Size: 182 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Valion Bio Announces Completion Of Needle-Free Oral Formulation Of Radiation Injury Drug Entolimod With Shear Kershman Laboratories
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
VBIO stock has given up its prior gain. Valion Bio shares were trading higher after the company announced the completion of formulation work under the company's ongoing program to develop a novel oral mucosal formulation of Entolimod with Shear Kershman Laboratories.
Valion Bio shares are trading higher after the company announced the completion of formulation work under the company's ongoing program to develop a novel oral mucosal formulation of Entolimod with Shear Kershman Laboratories.